Covance Drug Development moves to new clinical research unit in Dallas

Covance Drug Development recently relocated its Dallas clinical research unit to a new, fit-for-purpose clinical research facility in the same building.

The new unit expands the number of beds from 72 to 100. Patients will also have the opportunity to learn more about volunteering and participating in early stage clinical trials at the LabCorp patient service center co-located in the new unit.

“Our new Dallas facility combines advanced medical care with numerous volunteer-friendly amenities,” Herman Scholtz, vice president and general manager of Early Clinical Services, said. “We have invested in a highly customized facility designed to facilitate the safety and quality of our studies and to enhance our clients’ and volunteers’ experience. In addition, we are excited about the unique opportunity to educate patients about our clinical trials and complement our local patient recruitment capabilities through the future LabCorp patient service center. This innovative combination of resources is another illustration of the strategic and operational synergies that LabCorp and Covance are gaining through our combination.”

The new unit offers more than 55,000 square feet of space. It includes dedicated ophthalmology procedure rooms, a glucose clamp suite and dedicated screening and outpatient visit areas. There is also a current Good Manufacturing Practices pharmacy that includes three sterile and two non-sterile manufacturing suites.

The unit's advanced telemetry system allows the medical team to perform continuous, high-quality data monitoring that ensures improved monitoring of study participants and allowing for fast adjustments to treatment regimens.

The Dallas clinic employs approximately 75 medical and professional staff with plans to expand to 120 employees.